1. 422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. (9th November 2020) Authors: Middleton, Mark; Aroldi, Francesca; Sacco, Joseph; Milhem, Mohammed; Curti, Brendan; MBioeth, Ari VanderWalde; Baum, Scott; Samson, Adel; Pavlick, Anna; Chesney, Jason; Niu, Jiaxin; Rhodes, Terence; Bowles, Tawnya; Conry, Robert; Olsson-Brown, Anna; Laux, Douglas Earl; Kaufman, Howard; Bommareddy... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. (10th December 2020) Authors: Puzanov, Igor; Chesney, Jason; Collichio, Frances; Singh, Parminder; Milhem, Mohammed; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Yi, Min; Snyder, Wendy; Mehnert, Janice Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Issue 11 (November 2016) Authors: Hodi, F Stephen; Chesney, Jason; Pavlick, Anna C; Robert, Caroline; Grossmann, Kenneth F; McDermott, David F; Linette, Gerald P; Meyer, Nicolas; Giguere, Jeffrey K; Agarwala, Sanjiv S; Shaheen, Montaser; Ernstoff, Marc S; Minor, David R; Salama, April K; Taylor, Matthew H; Ott, Patrick A; Horak, ... Journal: Lancet oncology Issue: Volume 17:Issue 11(2016:Nov.) Page Start: 1558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). (6th November 2014) Authors: Andtbacka, Robert HI; Collichio, Frances A; Amatruda, Thomas; Senzer, Neil; Chesney, Jason; Delman, Keith; Spitler, Lynn; Puzanov, Igor; Agarwala, Sanjiv; Milhem, Mohammed; Harrington, Kevin; Middleton, Mark; Li, Ai; Shilkrut, Mark; Coffin, Robert; Kaufman, Howard Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Issue 1 (2nd January 2016) Authors: Klionsky, Daniel J; Abdelmohsen, Kotb; Abe, Akihisa; Abedin, Md Joynal; Abeliovich, Hagai; Acevedo Arozena, Abraham; Adachi, Hiroaki; Adams, Christopher M; Adams, Peter D; Adeli, Khosrow; Adhihetty, Peter J; Adler, Sharon G; Agam, Galila; Agarwal, Rajesh; Aghi, Manish K; Agnello, Maria; Agostinis... Journal: Autophagy Issue: Volume 12:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Melanoma of unknown primary: favorable survival persists in the immunotherapy era. (28th August 2022) Authors: Maharaj, Satish; Jain, Nikita; Al Bawaliz, Anas; Miller, Donald; Chesney, Jason Journal: International journal of dermatology Issue: Volume 62:Number 4(2023) Page Start: e236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. (15th April 2020) Authors: Sarnaik, Amod; Khushalani, Nikhil; Chesney, Jason; Kluger, Harriet; Curti, Brendan; Lewis, Karl; Medina, Theresa; Thomas, Sajeve; Pavlick, Anna; Whitman, Eric; Algarra, Salvador; Corrie, Pippa; Hamid, Omid; Lutzky, Jose; Olah, Judit; Weber, Jeffrey; Larkin, James; Shi, Wen; DiTrapani, Kelly; Qin,... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma. Issue 1 (February 2018) Authors: Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; Hutchins, Laura; Linette, Gerald; Triozzi, Pierre; Tan, Marcus C.B.; Brown, Russell E.; Nemunaitis, John; Whitman, Eric; Windham, Christopher; Lutzky, Jose; Downey, Gerald F.; Batty, Nicolas; Amatruda, Thomas Journal: Melanoma research Issue: Volume 28:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Issue 3 (June 2018) Authors: Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; Baum, Mary; Ranjan, Smita; Fraig, Mostafa; Batty, Nicolas Journal: Melanoma research Issue: Volume 28:Issue 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Issue 1 (30th October 2018) Authors: Mondal, Susmita; Roy, Debarshi; Sarkar Bhattacharya, Sayantani; Jin, Ling; Jung, Deokbeom; Zhang, Song; Kalogera, Eleftheria; Staub, Julie; Wang, Yaxian; Xuyang, Wen; Khurana, Ashwani; Chien, Jeremey; Telang, Sucheta; Chesney, Jason; Tapolsky, Gilles; Petras, Dzeja; Shridhar, Viji Journal: International journal of cancer Issue: Volume 144:Issue 1(2019) Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗